618385-01-6

Basic information

• Product Name: Vorapaxar
• Synonyms: Vorapaxar;Vorapaxar (SCH 530348);[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-carbamic acid ethyl ester;Voarapaxar;Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester;Ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]vinyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate;[(1R,3AR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-me
• CAS NO: 618385-01-6
• Molecular Formula: C29H33FN2O4
• Molecular Weight: 492.5817232
• Product Categories: API
• Mol File: 618385-01-6.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 676 °C at 760 mmHg
• Flash Point: 362.632 °C
• Appearance: /
• Density: 1.25 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.594
• Solubility: ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥10.64 mg/mL in EtOH with ultrasonic
• PKA: 12.49±0.60(Predicted)
• CAS DataBase Reference: Vorapaxar(CAS DataBase Reference)
• NIST Chemistry Reference: Vorapaxar(618385-01-6)
• EPA Substance Registry System: Vorapaxar(618385-01-6)

Safety Data

• Hazardous Substances Data: 618385-01-6(Hazardous Substances Data)

Usage

Description

Vorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor 1 (PAR1), also known as the thrombin receptor. It selectively targets PAR1 over other PARs, GPCRs, ion channels, and receptors, effectively inhibiting platelet aggregation induced by thrombin and haTRAP. Vorapaxar is used in the prevention of thrombotic cardiovascular events and has demonstrated the ability to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization.

Uses

Used in Cardiovascular Medicine:
Vorapaxar is used as an antagonist for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It functions by inhibiting platelet aggregation, which helps to reduce the risk of further cardiovascular complications.
Used in Pharmaceutical Formulations:
Vorapaxar is used as an active pharmaceutical ingredient in the development of formulations aimed at reducing thrombotic cardiovascular events. These formulations are specifically designed to target PAR1, providing a selective and effective treatment option for patients at risk of such events.

references

[1]. chackalamannil s & xia, y. thrombin receptor (par-1) antagonists as novel antithrombotic agents. expert opinion on therapeutic patents, 2006.16:493-505.[2]. chackalamannil s, wang y, greenlee w j et al. 2008. discovery of a novel, orally active himbacine-based thrombin receptor antagonist (sch 530348) with potent antiplatelet activity. j med chem, 2008,51: 3061-3064.

InChI:InChI=1/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1